Ipamorelin

Ipamorelin is a synthetic pentapeptide (a chain of five amino acids) and a potent growth hormone secretagogue. It acts as a ghrelin mimetic, binding to receptors in the brain to stimulate the pituitary gland to produce and release natural growth hormone (GH).

Key Benefits

Order Now

FDA-Approved Uses

⚠️ NOT FDA APPROVED FOR ANY HUMAN INDICATION ⚠️

Ipamorelin has no FDA-approved use. It remains an investigational research compound.

Regulatory Status (as of May 2026):

Conditions investigated in research (not approved):
1. Growth hormone deficiency in adults (off-label, research)
2. Anti-aging / body composition improvement
3. Muscle mass and recovery (research use)
4. Metabolic enhancement
5. Sleep quality improvement (GH is released predominantly during sleep)
6. Post-surgical recovery (limited human data)

WADA Status: Prohibited under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics.

Trade Names in the USA and Manufacturers

No FDA-approved brand or manufacturer in the US.

Ipamorelin is available as:
– Compounded formulation (503A pharmacies, legal status evolving — verify current FDA guidance before prescribing/dispensing)
– Research peptide from grey-market vendors (‘research use only’)

Commonly combined with CJC-1295 (a GHRH analogue) in clinical practice:
– Typical combined protocol: Ipamorelin 200 mcg + CJC-1295 100 mcg in a single nightly injection

Molecular identity: Pentapeptide (5 amino acids); MW ~711.85 g/mol
Molecular formula: C₃₈H₄₉N₉O₅

Dosage

⚠️ No FDA-approved dosing exists. The following reflects reported clinical/research practice.

Monotherapy (subcutaneous injection, off-label):
Typical dose: 200–300 mcg per injection
Frequency: Once daily at bedtime (most common) or up to 3x daily
Administration: Subcutaneous injection
Duration: Typically used in cycles of 8–12 weeks

Combination with CJC-1295 (common off-label protocol):
Ipamorelin: 200 mcg + CJC-1295: 100 mcg
Mixed in single nightly subcutaneous injection
Ipamorelin provides rapid 2-hour GH spike; CJC-1295 extends GH pulses for 6–8 days

Storage: Lyophilized powder stored below -18°C; reconstituted solution stable 2–3 weeks at 4°C.

Pricing

No commercial (FDA-approved) pricing.

Compounded ipamorelin (503A pharmacy, where legally available):
~$150–$350/month depending on dose and pharmacy

Research peptide vendors (unregulated):
~$40–$100 per vial (research use only)

Typically cash-pay; not covered by insurance.

Tips

– Ipamorelin’s 503A compounding status is in transition as of 2026. Before prescribing or dispensing, verify current FDA guidance — the landscape has changed multiple times since 2023.
– 503B compounding remains prohibited as of May 2026 — do not source from 503B facilities.
– Athletes: Ipamorelin is prohibited under WADA S2 — do not use if subject to anti-doping testing.
– Ipamorelin is more selective than GHRP-2 or GHRP-6 — it stimulates GH without significantly affecting cortisol or prolactin, which is considered a favorable selectivity profile.
– Often combined with CJC-1295 for enhanced and sustained GH release — consult a physician about combination protocols.
– Monitor IGF-1 levels during use; elevating IGF-1 above the normal range may carry theoretical cancer risk (as with all GH secretagogues).
– Inject at bedtime to align with the body’s natural GH secretion cycle (predominantly during deep sleep).

Side Effects

Commonly reported in clinical/research settings:
– Headache: Especially after first few injections; typically transient
– Flushing / warmth sensation shortly after injection
– Nausea: Mild; usually transient
– Dizziness
– Water retention / mild peripheral edema
– Injection site reactions: Pain, redness, swelling

Less common:
– Elevated blood glucose (GH promotes insulin resistance)
– Tingling or numbness (paresthesia) — related to fluid retention
– Fatigue (usually temporary)

Rare/theoretical:
– Elevated IGF-1: May carry theoretical cancer risk with prolonged elevation
– Antibody formation: Possible with prolonged use; not well-characterized in humans

Key advantage over other GHRPs (GHRP-2, GHRP-6):
– Does NOT significantly stimulate cortisol or prolactin release — more favorable hormonal selectivity profile

Contraindications

No formal contraindications established (no approved label).

Based on pharmacology and clinical experience:
– Active malignancy: Contraindicated — GH/IGF-1 elevation may promote tumor growth
– Diabetes mellitus: Use with caution — GH elevation worsens insulin sensitivity; monitor glucose
– Severe cardiovascular disease: Use with caution
– Athletes subject to WADA/USADA anti-doping: Prohibited under S2 — do not use
– Pregnancy and breastfeeding: No safety data; not recommended
– Children with open epiphyses: Not recommended — GH excess may cause abnormal growth
– Hypersensitivity to ipamorelin or excipients
– Active intracranial lesion or tumor: Contraindicated

Pharmacology

Ipamorelin is a synthetic pentapeptide (5 amino acids) growth hormone-releasing peptide (GHRP) and selective ghrelin receptor (GHSR-1a) agonist. Molecular formula: C₃₈H₄₉N₉O₅; MW: 711.85 g/mol.

It is distinct from GHRH analogues (like sermorelin or tesamorelin) in that it acts via the ghrelin receptor pathway rather than the GHRH receptor pathway — providing an additive/synergistic mechanism when combined with GHRH analogues. Administered subcutaneously.

Short plasma half-life (~2 hours), producing a brief, physiologic GH pulse. Lyophilized powder; stored desiccated below -18°C; stable in solution for 2–3 weeks at 4°C.

Mechanism of action

Ipamorelin selectively binds to and activates the GHSR-1a (ghrelin receptor / growth hormone secretagogue receptor 1a) on pituitary somatotroph cells.

Activation → stimulates pulsatile GH release from anterior pituitary.

Key selectivity advantage:
– Stimulates GH release WITHOUT significantly increasing cortisol, prolactin, or ACTH — unlike GHRP-2 and GHRP-6, which do increase these hormones.
– This selective GH stimulation makes ipamorelin a ‘clean’ GHRP with a more favorable hormonal profile.

Downstream effects (via GH and IGF-1):
– Promotes protein synthesis and lean muscle development
– Promotes lipolysis (fat breakdown)
– Supports bone mineral density
– May improve sleep quality (GH secretion linked to slow-wave sleep)

Combination with CJC-1295 (GHRH analogue):
– Ipamorelin acts via ghrelin receptor (rapid pulse); CJC-1295 acts via GHRH receptor (sustained release)
– Dual pathway activation produces additive GH stimulation — more comprehensive GH secretion than either alone

Result Claims from Different Companies

No FDA-approved manufacturer claims.

Academic and clinical research findings:
– GHRP selectivity studies: Demonstrated ipamorelin stimulates GH without cortisol or prolactin elevation — distinguishing it from earlier GHRPs (GHRP-2, GHRP-6).
– Small clinical studies: Reported improvements in body composition (increased lean mass, reduced fat mass), sleep quality, and recovery with off-label use.
– Combination data (CJC-1295 + ipamorelin): Clinical experience reports sustained IGF-1 elevation and reported improvements in energy, body composition, and recovery — most data from clinician case series, not RCTs.

⚠️ No Phase 3 RCT data exists for any indication. All efficacy claims are from small studies, case series, or clinician reports. Not FDA approved. No drug label claims can be made.

Disclaimer

This content about “Ipamorelin” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.